Personal information

Other IDs

SciProfiles: 2806249

Activities

Collapse all

Works (8)

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders

PLOS ONE
2023-05-01 | Journal article
DOI: 10.1371/journal.pone.0284925
Contributors: Hila Magen; Debdutta Bhattacharya; Abraham Avigdor; Lee Nevo; Shalev Fried; Amit Gibori; Einav G. Levin; Yaniv Lustig; Eden Shkury; Galia Rahav
Source: check_circle
Crossref

Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma

Cells
2023-03-16 | Journal article
DOI: 10.3390/cells12060913
Contributors: Olga Ostrovsky; Katia Beider; Hila Magen; Merav Leiba; Ralph D. Sanderson; Israel Vlodavsky; Arnon Nagler
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study

Cancers
2023-03-10 | Journal article
DOI: 10.3390/cancers15061710
Contributors: Eyal Lebel; Efstathios Kastritis; Giovanni Palladini; Paolo Milani; Foteini Theodorakakou; Shlomzion Aumann; Noa Lavi; Liat Shargian; Hila Magen; Yael Cohen et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Diagnostic Challenges and Solutions in Systemic Amyloidosis

International Journal of Molecular Sciences
2023-02-28 | Journal article
DOI: 10.3390/ijms24054655
Contributors: Rivka Goldis; Batia Kaplan; Olga (Lesya) Kukuy; Michael Arad; Hila Magen; Efrat Shavit-Stein; Amir Dori; Avi Livneh
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study

British Journal of Haematology
2023-01 | Journal article
DOI: 10.1111/bjh.18479
Contributors: Tamir Shragai; Hila Magen; Noa Lavi; Moshe Gatt; Svetlana Trestman; Miri Zektser; Chezi Ganzel; Osnat Jarchowsky; Tamar Berger; Tamar Tadmor et al.
Source: check_circle
Crossref

Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments

Therapeutic Advances in Hematology
2022-01 | Journal article
DOI: 10.1177/20406207211066173
Contributors: Hila Magen; Michal J. Simchen; Shira Erman; Abraham Avigdor
Source: check_circle
Crossref

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

British Journal of Haematology
2021-03 | Journal article
DOI: 10.1111/bjh.16980
Contributors: Ajai Chari; Paula Rodriguez‐Otero; Helen McCarthy; Kenshi Suzuki; Vania Hungria; Anna Sureda Balari; Aurore Perrot; Cyrille Hulin; Hila Magen; Shinsuke Iida et al.
Source: check_circle
Crossref

Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series

Clinical Lymphoma Myeloma and Leukemia
2020-12 | Journal article
DOI: 10.1016/j.clml.2020.07.016
Contributors: Hila Magen; Mika Geva; Yulia Volchik; Abraham Avigdor; Arnon Nagler
Source: check_circle
Crossref

Peer review (3 reviews for 2 publications/grants)

Review activity for BMJ open. (1)
Review activity for Clinical hematology international. (2)
How many people are using ORCID?